Quick Answer
Lucid Diagnostics Inc. reported Diluted EPS of $1.05 per share (loss) for fiscal year 2024.
Lucid Diagnostics Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2024 | -$1.05 | +16.7% |
| 2023 | -$1.26 | +18.7% |
| 2022 | -$1.55 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.10 | +60.0% | -25.0% |
| June 30, 2025 | -$0.08 | +65.2% | +84.6% |
| March 31, 2025 | -$0.52 | -30.0% | -108.0% |
| September 30, 2024 | -$0.25 | +26.5% | -8.7% |
| June 30, 2024 | -$0.23 | +14.8% | +42.5% |
| March 31, 2024 | -$0.40 | +0.0% | -17.6% |
| September 30, 2023 | -$0.34 | +12.8% | -25.9% |
| June 30, 2023 | -$0.27 | +34.1% | +32.5% |
- Lucid Diagnostics Inc. showed an increase of +16.7% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2024 period, Lucid Diagnostics Inc.’s diluted eps has grown by 32.3% (from $1.55 per share (loss) to $1.05 per share (loss)).
- The most recent figure is from Lucid Diagnostics Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 24, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: